Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 1997

View Archived Issues

Merck & Co. reports NOS inhibitors

5-HT2C/2A receptor antagonists from Egis

RXR-selective compounds disclosed by Allergan

Agents for psoriasis and cancers from Roche

NicOx reveals antiinflammatory/antithrombotic compounds with low toxicity

Merck & Co. discloses muscarinic antagonists for myopia

Agents for glaucoma revealed by Merck & Co.

Novel immunosuppressants prepared by Merck & Co.

Combination therapy approved by FDA for H. pylori eradication

Antifungal activity of nikkomycin Z alone and in combination with azoles

FDA advisory committee to review rituximab BLA

Crystal structure of BPI described by Xoma/UCLA

BioQuest to acquire Immune Complex Corporation

ERT reported to protect against AD

Axcan to distribute Ursofalk in Canada

Preclinical results reported by Lilly and Synaptic for potent and selective 5-HT1F agonist

Trega Biosciences and Northwest Neurologic sign drug discovery agreement

New antifungals under development

New polyene from SPA compared to amphotericin B

Hi-Tech Pharmacal obtains license to huperzine

New sordarin derivatives from Glaxo Wellcome

Agouron's IND for anticancer agent approved

Labopharm and Sepracor to develop new dosage forms of levalbuterol

Lilly and Serenics to codevelop psychopharmacologic and cardiovascular drugs

Triazole antifungals under development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...